About this condition
Bone Cancer — Hereditary
Hereditary bone cancers are predominantly associated with cancer predisposition syndromes. Li-Fraumeni syndrome (TP53) includes osteosarcoma as a core component — typically childhood/adolescent onset. Hereditary retinoblastoma (RB1) survivors have significantly elevated osteosarcoma risk, both within and outside radiation fields. These two syndromes account for the majority of hereditary osteosarcoma cases.
Hereditary multiple exostoses (HME/MHE, EXT1/EXT2) is the most common hereditary bone tumor condition, affecting ~1 in 50,000. EXT1 and EXT2 encode exostosin glycosyltransferases essential for heparan sulfate biosynthesis. HME causes multiple osteochondromas (benign cartilage-capped bone tumors) with ~2-5% lifetime risk of malignant transformation to chondrosarcoma — requiring lifelong orthopedic surveillance.
Additional hereditary bone tumor associations include Rothmund-Thomson syndrome (RECQL4 — osteosarcoma), Li-Fraumeni-like syndrome (CHEK2), Paget's disease of bone (SQSTM1/p62 — rare giant cell tumor/osteosarcoma transformation), and enchondromatosis (IDH1/IDH2 — Ollier disease/Maffucci syndrome with chondrosarcoma risk).
Hereditary multiple exostoses (EXT1/EXT2) affects 1 in 50,000 — causing benign bone tumors with 2-5% chondrosarcoma risk. Any new pain, growth, or change in an existing exostosis after skeletal maturity warrants urgent imaging.
- Gene locus
- TP53 (17p13.1), RB1 (13q14.2), EXT1 (8q24.11), EXT2 (11p11.2), RECQL4 (8q24.3)
